Phaseline

Companies › Direct Biologics

Direct Biologics: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 3; Respiratory, Immunology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ExoFlo
Bone marrow mesenchymal stem cell derived extracellular vesicles
–Phase 3Acute Respiratory Distress SyndromeNov 2027
DB-3Q
Acellular secretome proteins and extracellular vesicles from bone marrow-derived mesenchym
–Phase 2Crohn Disease (CD); Perianal Fistula Due to Crohn's DiseaseJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07625293DB-3QPhase 2Crohn Disease (CD)ImmunologyJun 2027
NCT06918808DB-3QPhase 2Perianal Fistula Due to Crohn's DiseaseImmunologyJul 2027
NCT05354141ExoFloPhase 3Acute Respiratory Distress SyndromeRespiratoryNov 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Genrix (Shanghai) Biopharmaceutical Mediar Therapeutics Bluefin Biomedicine Doron Therapeutics UnicoCell Biomed

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.